医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2013年
17期
88-89
,共2页
吕海建%巧红%吕英%孟红
呂海建%巧紅%呂英%孟紅
려해건%교홍%려영%맹홍
烧伤创面%愈合%重组人表皮生长因子(rhEGF)
燒傷創麵%愈閤%重組人錶皮生長因子(rhEGF)
소상창면%유합%중조인표피생장인자(rhEGF)
burn wound%healing%recombinant human epidermal growth factor (rhEGF)
目的观察重组人表皮生长因子(rhEGF)联合重组人碱性成纤维细胞生长因子(rhFGF)对烧伤创面愈合的影响。方法对60例烧伤患者,每例患者选择同一块深度烧伤创面的两部分,分别采用rhEGF法和rhEGF+ rhFGF法换药治疗,评价上述受试创面愈合后的瘢痕指数(SI)及愈合速度。结果 rhEGF+ rhFGF法残余创面愈合时间(12.45±8.42)天,明显少于rhEGF (29.7±10.12)天(t=2.225,P<0.05);两种方法创面分泌物细菌培养阳性率无显著性意义(t=1.684, P>0.05);愈后2年rhEGF法SI为8.92±1.78,明显低于rhEGF+ rhFGF法6.12±1.54(t=2.116,P<0.05);所有受试创面均无肿瘤形成、癌变等并发症发生。结论外用重组人表皮生长因子(rhEGF)联合重组人碱性成纤维细胞生长因子(rhFGF)治疗深度烧伤创面,能明显减少后期瘢痕的形成,远期疗效和安全性较好。
目的觀察重組人錶皮生長因子(rhEGF)聯閤重組人堿性成纖維細胞生長因子(rhFGF)對燒傷創麵愈閤的影響。方法對60例燒傷患者,每例患者選擇同一塊深度燒傷創麵的兩部分,分彆採用rhEGF法和rhEGF+ rhFGF法換藥治療,評價上述受試創麵愈閤後的瘢痕指數(SI)及愈閤速度。結果 rhEGF+ rhFGF法殘餘創麵愈閤時間(12.45±8.42)天,明顯少于rhEGF (29.7±10.12)天(t=2.225,P<0.05);兩種方法創麵分泌物細菌培養暘性率無顯著性意義(t=1.684, P>0.05);愈後2年rhEGF法SI為8.92±1.78,明顯低于rhEGF+ rhFGF法6.12±1.54(t=2.116,P<0.05);所有受試創麵均無腫瘤形成、癌變等併髮癥髮生。結論外用重組人錶皮生長因子(rhEGF)聯閤重組人堿性成纖維細胞生長因子(rhFGF)治療深度燒傷創麵,能明顯減少後期瘢痕的形成,遠期療效和安全性較好。
목적관찰중조인표피생장인자(rhEGF)연합중조인감성성섬유세포생장인자(rhFGF)대소상창면유합적영향。방법대60례소상환자,매례환자선택동일괴심도소상창면적량부분,분별채용rhEGF법화rhEGF+ rhFGF법환약치료,평개상술수시창면유합후적반흔지수(SI)급유합속도。결과 rhEGF+ rhFGF법잔여창면유합시간(12.45±8.42)천,명현소우rhEGF (29.7±10.12)천(t=2.225,P<0.05);량충방법창면분비물세균배양양성솔무현저성의의(t=1.684, P>0.05);유후2년rhEGF법SI위8.92±1.78,명현저우rhEGF+ rhFGF법6.12±1.54(t=2.116,P<0.05);소유수시창면균무종류형성、암변등병발증발생。결론외용중조인표피생장인자(rhEGF)연합중조인감성성섬유세포생장인자(rhFGF)치료심도소상창면,능명현감소후기반흔적형성,원기료효화안전성교호。
Objective To observe the effect of recombinant human epidermal growth factor (rhEGF) combined with recombinant human basic fibroblast growth factor (rhFGF) on burn wound healing. Methods 60 cases of burn patients, each patient selection of two parts of the same piece of deep burn wounds, respectively using rhEGF method and rhEGF+ rhFGF method for dressing change, the wound healing and scar index (SI) were evaluated after and. Results The rhEGF+ rhFGF method of residual wound healing time (12.45 ± 8.42) days were less than that of rhEGF (29.7 ± 10.12) days (t=2.225, P<0.05); The positive rate of bacterial culture was no significant difference in two methods (t=1.684, P>0.05); After 2 years index of SI (8.92 ± 1.78) in rhEGF were significantly lower than (6.12 ± 1.54)in rhFGF (t=2.116, P<0.05);; al subjects were no tumor formation, cancer and other complications. Conclusion the recombinant human epidermal growth factor (rhEGF) combined with recombinant human basic fibroblast growth factor (rhFGF) in treating deep burn wound can significantly reduce the scar formation, long-term efficacy and safety.